LILLY LAUNCHES TRIAL OF ORAL CANCER AGENT

A A

Eli Lilly has announced the initiation of a Phase III clinical trial studying enzastaurin, an investigational, multi-targeted agent for oral cancer.

The trial will investigate enzastaurin's potential in treating patients with non-Hodgkin's lymphoma, the most common cancer of the lymphatic system, which acts to defend the body against disease. Specifically, enzastaurin will be evaluated as a maintenance therapy in patients with diffuse large B-cell lymphoma who have achieved remission following first-line therapy.